Interviews
In this interview we speak to Chikwe Ihekweazu, current Director of the Nigeria Centre for Disease Control, about monkeypox, public trust, surveillance and the factors that influence preparedness.
Could board games be used as an educational tool to help teach and raise awareness around some of the major challenges in infectious diseases? In this interview we speak to Salam Abbara about the game she has helped develop, which aims to help medical students learn and understand antibiotic prescribing.
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘How could ethnicity-associated microbiomes contribute to personalized therapies?’, as we ask the authors about the factors that influence the microbiome composition, how these could be manipulated and the future of this field.
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
In this interview we speak to David Padley from the National Institute for Biological Standards and Control about his recent poster ‘Point-of-Care testing for HIV: specialist quality control materials are a necessity’, presented at ECCMID 2019.
In this interview we speak with Sarah Earle from the University of Oxford (UK) about her use of GWAS to understand more about Neisseria meningitidis and its transition from an asymptomatic commensal to an invasive pathogen.
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
We spoke to Sally Roberts (University of Birmingham, UK) at the recent Microbiology Society Conference (8–11 April, Belfast, UK) about her lab’s models for studying HPV and the virus–host interactions that have been uncovered as a result of this.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Could targeting neighboring bacterial populations help to combat bacterial vaginosis?’, as we ask the authors about the challenges in treating bacterial vaginosis (BV) and the future of this field.
